Angela Stupi
Rheumatology · Cranberry Twp, PANPI 1619975984
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 55 manufacturers reported payments, led by Amgen at 50.1% of the total. Reporting peaked in 2019 at $57,883 and has fallen 78.9% since, to $12,241 in 2025. Among rheumatology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,385 payments — averaging $56.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$68K
- Bristol Myers Squibb$17K
- AbbVie$9K
- Regeneron Healthcare Solutions, Inc.$8K
- Johnson & Johnson$5K
- AstraZeneca$4K
- plus $24K from 49 others
Across 21 payments — averaging $9577.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$155K
- Janssen Research & Development, LLC$21K
- AbbVie$10K
- Gilead$8K
- Eli Lilly$5K
- Bristol Myers Squibb$3K
- plus $30 from 1 others
What the payments were for
- Consulting fees$8,4216%
- Speaking & faculty fees$71,61153%
- Grants$1,2001%
- Travel & lodging$7,6666%
- Food & beverage$45,64534%
- Education$1860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$134,730 in reported general payments places this provider in the 90th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 48 | $906,764 |
| KrystexxaPegloticase | 14 | $824,789 |
| OrenciaAbatacept/Maltose | 55 | $302,730 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 32 | $259,785 |
| SaphneloAnifrolumab-Fnia | 35 | $176,287 |
| BenlystaBelimumab | 32 | $113,554 |
| Simponi AriaGolimumab | 16 | $105,554 |
| ActemraTocilizumab | 50 | $97,355 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $88,143 |
| ProliaDenosumab | 48 | $82,642 |
| RasuvoMethotrexate/Pf | 21 | $11,732 |
| Diclofenac Sodium | 11 | $6,505 |
| Zoledronic AcidZoledronic Acid/Mannitol-Water | 26 | $4,215 |
| Hydroxychloroquine Sulfate | 27 | $561 |
| MethotrexateMethotrexate Sodium | 11 | $292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa, Prolia | $67,504 | $907,43262 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $25 | $906,76448 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $799 | $302,73055 claims |
| Grifols USA, LLCGamunex-C | $72 | $259,78532 claims |
| AstraZenecaSaphnelo | $4,133 | $176,28735 claims |
| GSKBenlysta | $1,797 | $113,55432 claims |
| Johnson & JohnsonSimponi Aria | $5,020 | $105,55416 claims |
| Medexus Pharma, Inc.Rasuvo | $95 | $11,73221 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $141 | $11612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 351 rheumatology providers in Pennsylvania.
Other rheumatology in Cranberry Twp
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
- Alan KivitzDuncansville$936K
- Paula HerringNewtown Square$920K
- Rohit AggarwalPittsburgh$810K
- Frederick MurphyDuncansville$494K
- Peter MerkelRadnor$479K
- Martin BergmanRidley Park$458K
- Alexis Ogdie-BeattyPhiladelphia$433K
- Ellen FieldBethlehem$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.